F A Shepherd

Summary

Affiliation: St. Michael's Hospital
Country: Canada

Publications

  1. ncbi request reprint Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
  2. ncbi request reprint Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
    F A Shepherd
    Department of Medicine of the Toronto Hospital, Canada
    J Clin Oncol 16:1736-42. 1998
  3. ncbi request reprint Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
    F A Shepherd
    Toronto Hospital, Ontario, Canada
    Lung Cancer 17:S121-36. 1997
  4. ncbi request reprint Treatment of Kaposi's sarcoma after solid organ transplantation
    F A Shepherd
    Department of Medicine, The Multi Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 15:2371-7. 1997
  5. doi request reprint Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    Geoffrey Liu
    Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Canada
    J Thorac Oncol 7:316-22. 2012
  6. ncbi request reprint Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
  7. pmc Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study
    F A Shepherd
    Interdepartmental Division of Oncology of the University of Toronto, Ontario, Canada
    Br J Cancer 78:683-5. 1998
  8. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
  9. doi request reprint Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    R Goodwin
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 21:2220-6. 2010
  10. ncbi request reprint Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials
    F A Shepherd
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Semin Oncol 28:4-9. 2001

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
    ..Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life...
  2. ncbi request reprint Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
    F A Shepherd
    Department of Medicine of the Toronto Hospital, Canada
    J Clin Oncol 16:1736-42. 1998
    ..These observations led to our trial of zidovudine with two dose levels of interferon alfa...
  3. ncbi request reprint Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
    F A Shepherd
    Toronto Hospital, Ontario, Canada
    Lung Cancer 17:S121-36. 1997
    ..It remains only speculative at this time as to whether manipulation of abnormal genes in malignant cells will be clinically possible, and whether treatment of this sort may be applied in an adjuvant setting...
  4. ncbi request reprint Treatment of Kaposi's sarcoma after solid organ transplantation
    F A Shepherd
    Department of Medicine, The Multi Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 15:2371-7. 1997
    ....
  5. doi request reprint Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    Geoffrey Liu
    Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Canada
    J Thorac Oncol 7:316-22. 2012
    ..Predictive and prognostic analyses of epidermal growth factor receptor (EGFR), ABCG2, and AKT1 genetic polymorphisms were performed...
  6. ncbi request reprint Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
    ..To determine whether an intensive weekly chemotherapy regimen plus thoracic irradiation is superior to standard chemotherapy in the treatment of extensive-stage small-cell lung cancer (ESCLC)...
  7. pmc Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study
    F A Shepherd
    Interdepartmental Division of Oncology of the University of Toronto, Ontario, Canada
    Br J Cancer 78:683-5. 1998
    ..5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment...
  8. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
    ..To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin...
  9. doi request reprint Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    R Goodwin
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 21:2220-6. 2010
    ....
  10. ncbi request reprint Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials
    F A Shepherd
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Semin Oncol 28:4-9. 2001
    ..The adverse events observed were predictable, tolerable, and manageable. These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer...
  11. doi request reprint An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    A M Horgan
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 22:1805-11. 2011
    ..Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel...
  12. ncbi request reprint Validity of sexual histories in a prospective study of male sexual contacts of men with AIDS or an AIDS-related condition
    R A Coates
    Department of Preventive Medicine and Biostatistics, Faculty of Medicine, University of Toronto, Ontario, Canada
    Am J Epidemiol 128:719-28. 1988
    ..However, some caution may be necessary in interpreting the results for some activities (anal digit insertion, anilingus) since agreement is less satisfactory for these activities...
  13. ncbi request reprint Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group
    F A Shepherd
    The Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, 5 104, Toronto, Ontario, M5G 2M9, Canada
    Cancer 92:595-600. 2001
    ..This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin...
  14. doi request reprint The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
    P Wheatley-Price
    Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Ann Oncol 21:2023-8. 2010
    ..Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups...
  15. ncbi request reprint Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer
    F A Shepherd
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario
    Semin Oncol 28:30-7. 2001
    ..Miscellaneous treatments, including monoclonal antibody therapy, tamoxifen, and growth factor inhibition have not yet been shown to have a role in the treatment of SCLC. Semin Oncol 28 (suppl 4):30-37...
  16. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    F A Shepherd
    Division of Medical Oncology, Department of Medicine, Princess Margaret Hospital, 610 University Avenue, 5 104, University of Toronto, Ont, Toronto, Canada, M5G 2M9
    Lung Cancer 34:S81-9. 2001
    ..Numerous other anti-angiogenesis agents are in early clinical trials, but have not been evaluated in lung cancer yet...
  17. ncbi request reprint Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin
    D J Stewart
    Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada
    J Clin Oncol 15:1897-905. 1997
    ....
  18. ncbi request reprint Economic issues in lung cancer: a review
    P J Goodwin
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 16:3900-12. 1998
    ..It is estimated that lung cancer is responsible for 20% of all cancer care costs. Concerns exist that this expenditure is associated with questionable benefits...
  19. pmc Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
    T Reiman
    Department of Medicine, Dalhousie University and Department of Oncology, Saint John Regional Hospital, Saint John, NB, Canada
    Ann Oncol 23:86-93. 2012
    ..We explored this further in additional patients from JBR.10 and the other three trials...
  20. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
    ..The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety...
  21. doi request reprint The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
    P Wheatley-Price
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario
    Ann Oncol 21:232-7. 2010
    ..Previous studies reported that women survive longer than men, but experience greater toxicity, when treated for small-cell lung cancer (SCLC)...
  22. ncbi request reprint Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
    ..Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC...
  23. pmc Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
    C Q Zhu
    Division of Applied Molecular Oncology, Ontario Cancer Institute, Ontario, Toronto, Canada
    Br J Cancer 94:1452-9. 2006
    ..16, P=0.03). These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC...
  24. ncbi request reprint Cancer incidence among Canadian kidney transplant recipients
    P J Villeneuve
    Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada
    Am J Transplant 7:941-8. 2007
    ..Our findings underscore the need for increased vigilance among kidney transplant recipients for cancers at sites where there are no population-based screening programs in place...
  25. pmc Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk
    G Liu
    Department of Medicine, Division of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Oncogene 30:3295-304. 2011
    ..These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway...
  26. ncbi request reprint Comparison of three HIV antigen detection kits in sequential sera from a cohort of homosexual men
    S E Read
    Department of Pediatrics, Faculty of Medicine, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 4:717-23. 1991
    ..There are significant differences in the performance characteristics of these commercial products for the detection of HIV antigen in serum...